Inactivated Polio Vaccine (IPV) Mucosal Immunity Boosting Trial in Kalutara District, Sri Lanka 2016
Not Applicable
Recruiting
- Conditions
- Polio virus immunity
- Registration Number
- SLCTR/2016/010
- Lead Sponsor
- World Health Organization Head Quarters
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
1. Children aged 10-12 years
2. Residence in the selected areas of the Kalutara District
3. Parent/Guardian provides consent for child’s participation
Exclusion Criteria
1. Contraindication for venipuncture
2. Sick child requiring hospitalization for acute or chronic illness
3. Diagnosis or suspicion of congenital immunodeficiency disorder in the subject or an immediate family member
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does inactivated polio vaccine (IPV) enhance to boost mucosal immunity against poliovirus in Sri Lanka's population?
How does the inactivated polio vaccine (IPV) compare to oral polio vaccine (OPV) in inducing mucosal immunity in low-prevalence regions like Kalutara District?
What biomarkers are associated with enhanced mucosal immune response following IPV administration in polio-endemic or post-endemic areas?
What adverse events are reported with inactivated polio vaccine (IPV) in mucosal immunity boosting strategies, and how are they managed in field trials?
Are there combination approaches involving inactivated polio vaccine (IPV) and other immunomodulators to improve serotype-specific immunity in polio virus immunity studies?